Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson’s disease

Sardoiwala, Mohammed Nadim; Mohanbhai, Soni Jignesh; Karmakar, Surajit; Choudhury, Subhasree Roy

doi:10.1016/j.msec.2021.112602

Cited by 6 publications

(22 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, size and morphological evaluation showed unimodal, stable, and nanosized particles that support earlier reports that have demonstrated controllable polydopamine nanoparticle synthesis . In general, solution oxidation methods lead to a wide range of size of nanoparticles from 50 to 150 nm. , However, reverse emulsification can help control its size variation, which is confirmed by DLS and TEM results. A higher percentage of 50% melatonin drug loading with 94.6% encapsulation efficiency has been achieved with a reverse emulsification strategy.…”

Section: Resultssupporting

confidence: 89%

“…11 In general, solution oxidation methods lead to a wide range of size of nanoparticles from 50 to 150 nm. 15,16 However, reverse emulsification can help control its size variation, which is confirmed by DLS and TEM results. A higher percentage of 50% melatonin drug loading with 94.6% encapsulation efficiency has been achieved with a reverse emulsification strategy.…”

Section: Characterization Of the Prepared Nanoparticlesmentioning

confidence: 57%

See 1 more Smart Citation

Improved Melatonin Delivery by a Size-Controlled Polydopamine Nanoformulation Attenuates Preclinical Diabetic Retinopathy

Sardoiwala¹,

Nagpal²,

Bhatt³

et al. 2023

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Oxidative stress, reactive oxygen species generation, and overexpression of VEGF are signatory events in diabetic retinopathy. The downregulation of VEGF and anti-inflammatory action pave the way for diabetic retinopathy (DR) therapy. In that, lower absorption kinetics of melatonin limits its immense therapeutic potential. Hence, we have demonstrated a reverse microemulsion method to synthesize melatonin-loaded polydopamine nanoparticles to replenish both at a single platform with an improved melatonin delivery profile. The study has evaluated in vitro and in vivo protection efficiency of biocompatible melatonin-loaded polydopamine nanoparticles (MPDANPs). The protection mechanism was explained by downregulation of VEGF, CASPASE3, and PKCδ against high-glucose/streptozotocin (STZ)-induced insults, in vitro and in vivo. The anti-inflammatory and antiangiogenic effect and potential of MPDANPs to enhance melatonin in vivo stability with prolonged circulation time have proved MPDANPs as a potential therapeutic candidate in DR management. The DR therapeutic potential of MPDANPs has been arbitrated by improving the bioavailability of melatonin and inhibition of VEGF–PKCδ crosstalk in vivo.

show abstract

Section: Resultssupporting

confidence: 89%

Section: Characterization Of the Prepared Nanoparticlesmentioning

confidence: 57%

Improved Melatonin Delivery by a Size-Controlled Polydopamine Nanoformulation Attenuates Preclinical Diabetic Retinopathy

Sardoiwala¹,

Nagpal²,

Bhatt³

et al. 2023

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hence, we prepared polydopamine nanoparticles (PNPs) by encapsulating melatonin. Polydopamine nanoparticles are also reported as biocompatible and ROS scavengers. − Besides that, dopamine deficiency is also reported in the progression of DR . Recently, melatonin-loaded nanoparticles have shown protective effects in the treatment of diabetic retinopathy by recovering the retinal inflammation. , Herein, we have developed melatonin-loaded polydopamine nanoparticles (mPNPs) in the development of DR treatment by restoring neural damage of the retina.…”

Section: Introductionmentioning

confidence: 99%

“…In Figure 2B, the release profile of mPNPs has shown Gompertz as the best fitted model that divulges a Fickian transport mechanism as the drug release mechanism of the melatonin from the mPNPs, which is in line with the existing report of the polydopamine-based nanocarrier system. 13 Here, the Fickian kinetics means that the diffusion of the drug is mediated by the slower degradation of the carrier.…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin-Polydopamine Nanoformulation Prevents Retinal Neurodegeneration in a Preclinical Model of Diabetic Retinopathy

Sardoiwala,

Biswal,

Sahu

et al. 2024

ACS Appl. Nano Mater.

Self Cite

View full text Add to dashboard Cite

Reactive oxygen species, inflammation, angiogenesis, and retinal neurodegeneration lead to diabetic retinopathy (DR) progression. The inhibition of VEGF and prevention from retinal neurodegeneration pave the way to developing DR treatment. Melatonin is a potent anti-inflammatory agent and a promising therapeutic candidate for DR therapy. However, melatonin has a lower absorption kinetic that limits its therapeutic efficiency. Recently, nanotechnology-based nanodrug delivery systems have gained attention to overcome limitations of existing potent drugs. Therefore, we have prepared melatonin-loaded polydopamine nanoparticles to improve the melatonin release profile that result in endowed therapeutic potential of melatonin. The evaluation of in vitro and in vivo DR studies have shown the protection efficiency of our nanoformulation. The mechanism of protection is attributed to downregulated vascular endothelial growth factor (VEGF), inhibited CASPASE3, and upregulated nerve/glial antigen 2 (NG2) and choline acetyltransferase (CHAT) that reflect the antiangiogenesis, antiapoptosis, and neuroprotective potential of our nanoformulation in the preclinical DR model. Thus, the antiangiogenesis and retinal neuroprotection efficiency of melatonin-loaded polydopamine nanoparticles suggests our nanoformulation as a promising nanotherapeutic agent for DR treatment.

show abstract

Stimulus-responsive curcumin-based polydopamine nanoparticles for targeting Parkinson’s disease by modulating α-synuclein aggregation and reactive oxygen species

Zhang

et al. 2023

Chemical Engineering Journal

View full text Add to dashboard Cite

Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson’s disease

Cited by 6 publications

References 40 publications

Improved Melatonin Delivery by a Size-Controlled Polydopamine Nanoformulation Attenuates Preclinical Diabetic Retinopathy

Improved Melatonin Delivery by a Size-Controlled Polydopamine Nanoformulation Attenuates Preclinical Diabetic Retinopathy

Melatonin-Polydopamine Nanoformulation Prevents Retinal Neurodegeneration in a Preclinical Model of Diabetic Retinopathy

Stimulus-responsive curcumin-based polydopamine nanoparticles for targeting Parkinson’s disease by modulating α-synuclein aggregation and reactive oxygen species

Contact Info

Product

Resources

About